These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 28010146)

  • 1. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea.
    Ha D; Choi Y; Kim DU; Chung KH; Lee EK
    Clin Ther; 2011 Jul; 33(7):926-32. PubMed ID: 21715008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways.
    Kim S; Cho H; Kim J; Lee K; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):119-126. PubMed ID: 32308058
    [No Abstract]   [Full Text] [Related]  

  • 4. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years.
    Kim S; Kim J; Cho H; Lee K; Ryu C; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):479-488. PubMed ID: 33275463
    [No Abstract]   [Full Text] [Related]  

  • 5. Eight-year experience of using HTA in drug reimbursement: South Korea.
    Bae EY; Hong JM; Kwon HY; Jang S; Lee HJ; Bae S; Yang BM
    Health Policy; 2016 Jun; 120(6):612-20. PubMed ID: 27086557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
    Zaric GS; O'brien BJ
    Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation on the first 2 years of the positive list system in South Korea.
    Park SE; Lim SH; Choi HW; Lee SM; Kim DW; Yim EY; Kim KH; Yi SY
    Health Policy; 2012 Jan; 104(1):32-9. PubMed ID: 22001369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System.
    Yoo SL; Kim DJ; Lee SM; Kang WG; Kim SY; Lee JH; Suh DC
    Int J Environ Res Public Health; 2019 Jan; 16(2):. PubMed ID: 30669602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Industry Survey on Unmet Needs in South Korea's New Drug Listing System.
    Kim S; Lee JY; Cho SH; Shin EJ; Kim M; Lee JH
    Ther Innov Regul Sci; 2023 Jul; 57(4):759-768. PubMed ID: 37183236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
    Pauwels K; Huys I; De Nys K; Casteels M; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):859-68. PubMed ID: 25978862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
    Yong JH; Beca J; Hoch JS
    Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?
    Chim L; Kelly PJ; Salkeld G; Stockler MR
    Pharmacoeconomics; 2010; 28(6):463-75. PubMed ID: 20465315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Health Technology Assessment in Drug Policies: Korea.
    Bae EY
    Value Health Reg Issues; 2019 May; 18():24-29. PubMed ID: 30419447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer.
    McCullagh L; Schmitz S; Barry M; Walsh C
    Pharmacoeconomics; 2017 Nov; 35(11):1177-1185. PubMed ID: 28770453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea.
    Bae EY; Lee EK
    Value Health; 2009; 12 Suppl 3():S36-41. PubMed ID: 20586979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.
    Kwon SH; Park SK; Byun JH; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):411-419. PubMed ID: 28019130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic evaluation in Ireland: a review of the process.
    Tilson L; O'Leary A; Usher C; Barry M
    Pharmacoeconomics; 2010; 28(4):307-22. PubMed ID: 20222754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes?
    McGuire A; Drummond M; Martin M; Justo N
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):599-605. PubMed ID: 26176751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.